Determination of lg G lg M Levels in Individuals Receiving BNT162b2 and CoronaVac Vaccine

Abstract<o:p></o:p>

Objective: COVID-19 is

an acute respiratory disease caused by the SARS-CoV-2 virus. Vaccination is the

most effective and economical way to prevent the disease. In this study, the

immune response in individuals who received two different COVID-19 vaccines (BioNTech

and CoronaVac) was measured to determine changes in antibody levels over time.<o:p></o:p>

Methods: A total of

67 individuals who received two doses of Covid-19 vaccine (BioNTech: n=42,

CoronaVac: n=25) were included in the study. Blood samples were collected from

all volunteers three times: before vaccination, 14 days after the first dose,

and 14 days after the second dose. Serum immunoglobulin G (IgG) and

immunoglobulin M (IgM) levels in the samples were measured quantitatively using

the ELISA method. IgM and IgG levels were measured at baseline (IgG0, IgM0),

after the first vaccine (IgG1, IgM1), and after the second vaccine (IgG2,

IgM2), and changes in antibody levels over time were evaluated. The difference

in IgG and IgM levels created by each vaccine was evaluated using the Tukey

test following a one-way ANOVA test. <o:p></o:p>

Results: After the

second dose of vaccination, serum IgG levels in individuals who received the

CoronaVac and BioNTech vaccines increased significantly compared to baseline.

IgM levels remained unchanged after two doses in individuals who received

CoronaVac, while they decreased significantly after the first and second doses

in individuals who received BioNTech compared to baseline (p=0.009).<o:p></o:p>

Conclusion: Two doses of

vaccine are necessary for a strong and lasting antibody response. BioNTech

vaccine induces higher IgG levels. Completing both doses of vaccines during

epidemics is important for controlling epidemics and achieving herd immunity.<o:p></o:p>

Keywords: Antibody, Covid-19,

IgG, IgM<o:p></o:p>